-

Dr. Andrew Huberman Joins Hims & Hers Board of Directors

World-renowned neuroscientist and tenured Stanford professor brings valuable expertise to the company on making the latest health innovations accessible and actionable

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company’s Board of Directors.

Dr. Huberman is a world-renowned neuroscientist and tenured professor in the Departments of Neurobiology and Ophthalmology at Stanford University School of Medicine. He has authored or co-authored more than 75 peer-reviewed articles in respected scientific journals including Nature, Science, Cell, Neuron, Current Biology, and Journal of Neuroscience. Research from his laboratory at Stanford, the Huberman Laboratory, has advanced our understanding of brain development, neural plasticity, and the neural mechanisms of stress and resilience.

Dr. Huberman has become a trusted cultural voice on the latest health and wellness science for people all over the world. As the host of the podcast Huberman Lab, the most popular health and science podcast in the world, he translates science into real-life protocols for millions of people, and his book Protocols: An Operating Manual for the Human Body is a #1 New York Times bestseller.

“Andrew Huberman has done more than almost anyone to make rigorous science accessible and actionable for millions of people,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “As we continue to build the future of personalized, science-backed healthcare, his expertise in neuroscience and human health will sharpen how we think about the science behind our offerings. We’re thrilled to welcome him to our board of directors.”

“Tools to significantly improve human health are emerging faster than ever,” said Andrew Huberman. “Everyone deserves access to the best possible healthcare and tools to feel great. Hims & Hers provides the ideal platform to deliver personalized health. I’m delighted to join the board of Hims & Hers because they are clearly the leaders in this effort, and are transforming an industry of personalized healthcare that, in the past, has been too slow to prioritize everyday people. I’m incredibly proud to be part of the mission to set a new standard for delivering personalized healthcare that allows everyone to feel their absolute best in terms of health, vigor, and longevity.”

Dr. Huberman joins a multi-disciplinary board that includes experts in clinical practice, pharmaceuticals, regulatory affairs, retail, technology, and foreign policy. He will also serve as a scientific and brand marketing advisor to Hims & Hers and separately provide additional marketing support to the company through the Huberman Lab podcast.

About Hims & Hers Health, Inc.

Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.himsandhershealth.com.

Contacts

Press Contact
Abby Reisinger-Moley
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Press Contact
Abby Reisinger-Moley
press@forhims.com

More News From Hims & Hers

Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026. “In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them,” said Andrew Dudum, co-founder and CEO. “Everythin...

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly’s obesity med...

Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grüns®, Medjet®, Tonal™, and Viome™. The program launched in March with two partners and has grown to include 14, with benefits designed to support subscribers’ whole-body health, including through a GLP-1 weight loss journey. "Building health is an everyday activity. It starts with understanding your body and co...
Back to Newsroom